A Phase 2 interventional study of Sitravatinib and Tislelizumab in Esophageal Squamous Cell Carcinoma, sponsored by BeiGene. Terminated at 31 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-13.
Sponsored by BeiGene · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma — 13 open to participants now, 15 under way, 1 of them phase 3. tislelizumab · Esophageal Squamous Cell Carcinoma.
Among the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma, this one is the 7th largest by enrollment, is one of 10 that started in 2022, is one of 14 in phase 2, and was the 10th registered.
676 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.
Browse Esophageal Squamous Cell Carcinoma studies →13 of the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma are open now, in 4 countries. Recruiting first, the newest first:
BeOne Medicines · Sites in Japan
Ages 18+
BeOne Medicines · Sites in United States
Ages 18+
Ming-Yu Lien · Sites in Taiwan
Ages 20+
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Sichuan University · Sites in China
Ages 18–75
By country, each count listing its studies:
tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 17 · Phase 3 4 · Phase 4 1
First in 2018; this study’s year is marked. 10 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is above the median of 64 across 564 interventional studies indexed under Esophageal Squamous Cell Carcinoma.
Median enrollment 50 across the 23 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
10 studies in Esophageal Squamous Cell Carcinoma by BeOne Medicines: 2 open now, 2 under way, none of them phase 3. Of 8 finished, 6 (75%) have results posted.
Among the 10 studies in Esophageal Squamous Cell Carcinoma by BeOne Medicines, this one is the 6th largest by enrollment, is the only one that started in 2022, is one of 7 in phase 2, and was the 7th registered.
BeOne Medicines’s Esophageal Squamous Cell Carcinoma studies by the year they started, since 2017.
1 of the studies testing tislelizumab in Esophageal Squamous Cell Carcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07317609Shanghai Zhongshan HospitalNeoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02) | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among BeOne Medicines’s 10 in Esophageal Squamous Cell Carcinoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study aimed to evaluate the efficacy and safety of sitravatinib in combination with tislelizumab as a second- or third-line treatment for participants with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma (ESCC) who experienced disease progression following prior systemic chemotherapy.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sitravatinib administered orally and tislelizumab administered intravenously
Drug: Sitravatinib · Drug: Tislelizumab
Sitravatinib administered orally
Drug: Sitravatinib
Investigators chose between docetaxel or irinotecan
Drug: Docetaxel · Drug: Irinotecan
100 mg orally once daily
Also known as: BGB-9468
200 mg intravenously once every 3 weeks
Also known as: BGB-A317
75 milligrams per square meter of body surface area (mg/m2) intravenously on Day 1 of every 21-day cycle
125 mg/m2 intravenously on Days 1 and 8 of every 21-day cycle
Arms A and C: Overall Response Rate (ORR)
ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as assessed by the investigator per the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1.
Time frame: Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)
Duration of Response (DOR)
Defined as the time from the first occurrence of a documented objective response to the time of documented disease progression assessed by the investigator or death from any cause, whichever occurred first, in all randomized participants with documented objective responses.
Time frame: Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)
Overall Survival (OS)
Defined as the time from randomization until the date of death due to any cause. Kaplan-Meier methodology was used to estimate the median OS.
Time frame: Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)
Disease Control Rate (DCR)
Defined as the percentage of participants whose best overall response is complete response, partial response, or stable disease, as assessed by the investigator per RECIST v1.1
Time frame: Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)
Clinical Benefit Rate (CBR)
Defined as the percentage of participants with a complete response, partial response, or durable stable disease (defined as stable disease for 24 weeks or longer, as assessed by the investigator per RECIST v.1.1.
Time frame: Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)
Progression Free Survival (PFS)
Defined as the time from randomization until first documentation of disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurred first. Kaplan-Meier methodology was used to estimate the median PFS.
Time frame: Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)
Arms A and B: Overall Response Rate (ORR)
ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as assessed by the investigator per RECIST v1.1. Analysis of ORR in Arm A compared to Arm B was specified as a secondary endpoint in the Protocol (please see the primary outcome measure for Arm C results)
Time frame: Through study completion data cut-off date of February 26th, 2024 (maximum time on study was 12 months)
Number of Participants With Adverse Events
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, and vital signs, according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0
Time frame: From the first dose to 30 days after the last dose or the start of new anticancer therapy, whichever occurred first (maximum time on treatment was 8.9 months for Arm A, 7.7 months for Arm B, and 8.0 months for Arm C).
Participants were enrolled across multiple study centers in China. The first participant provided consent on October 3, 2022, and the last participant completed the study on February 26, 2024.
| Milestone | Arm A: Tislelizumab + Sitravatinib | Arm B: Sitravatinib | Arm C: Investigator-chosen Chemotherapy (ICC) |
|---|---|---|---|
| Started | 39 | 19 | 38 |
| Treated | 39 | 19 | 34 |
| Completed | 0 | 0 | 0 |
| Not completed | 39 | 19 | 38 |
| Withdrew: Withdrawal by subject | 1 | 1 | 3 |
| Withdrew: Study terminated by sponsor | 18 | 13 | 16 |
| Withdrew: Death | 20 | 5 | 19 |
ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as assessed by the investigator per the Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1.
| percentage of participants | Arm A: Tislelizumab + Sitravatinib | Arm C: Investigator-chosen Chemotherapy (ICC) |
|---|---|---|
| Arms A and C: Overall Response Rate (ORR) | 10.3 (2.9 to 24.2) | 5.3 (0.6 to 17.7) |
Defined as the time from the first occurrence of a documented objective response to the time of documented disease progression assessed by the investigator or death from any cause, whichever occurred first, in all randomized participants with documented objective responses.
| months | Arm A: Tislelizumab + Sitravatinib | Arm B: Sitravatinib | Arm C: Investigator-chosen Chemotherapy (ICC) |
|---|---|---|---|
| Duration of Response (DOR) | 5.2 (4.4 to NA) | 4.6 (2.8 to NA) | NA (2.8 to NA) |
Defined as the time from randomization until the date of death due to any cause. Kaplan-Meier methodology was used to estimate the median OS.
| months | Arm A: Tislelizumab + Sitravatinib | Arm B: Sitravatinib | Arm C: Investigator-chosen Chemotherapy (ICC) |
|---|---|---|---|
| Overall Survival (OS) | 6.1 (3.4 to 7.5) | 9.1 (6.5 to NA) | 5.5 (4.7 to 6.6) |
Defined as the percentage of participants whose best overall response is complete response, partial response, or stable disease, as assessed by the investigator per RECIST v1.1
| percentage of participants | Arm A: Tislelizumab + Sitravatinib | Arm B: Sitravatinib | Arm C: Investigator-chosen Chemotherapy (ICC) |
|---|---|---|---|
| Disease Control Rate (DCR) | 64.1 (47.2 to 78.8) | 63.2 (38.4 to 83.7) | 42.1 (26.3 to 59.2) |
Defined as the percentage of participants with a complete response, partial response, or durable stable disease (defined as stable disease for 24 weeks or longer, as assessed by the investigator per RECIST v.1.1.
| percentage of participants | Arm A: Tislelizumab + Sitravatinib | Arm B: Sitravatinib | Arm C: Investigator-chosen Chemotherapy (ICC) |
|---|---|---|---|
| Clinical Benefit Rate (CBR) | 17.9 (7.5 to 33.5) | 26.3 (9.1 to 51.2) | 5.3 (0.6 to 17.7) |
Defined as the time from randomization until first documentation of disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurred first. Kaplan-Meier methodology was used to estimate the median PFS.
| months | Arm A: Tislelizumab + Sitravatinib | Arm B: Sitravatinib | Arm C: Investigator-chosen Chemotherapy (ICC) |
|---|---|---|---|
| Progression Free Survival (PFS) | 3.4 (2.1 to 5.6) | 5.6 (2.1 to NA) | 2.6 (1.5 to 3.8) |
ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) as assessed by the investigator per RECIST v1.1. Analysis of ORR in Arm A compared to Arm B was specified as a secondary endpoint in the Protocol (please see the primary outcome measure for Arm C results)
| percentage of participants | Arm A: Tislelizumab + Sitravatinib | Arm B: Sitravatinib |
|---|---|---|
| Arms A and B: Overall Response Rate (ORR) | 10.3 (2.9 to 24.2) | 21.1 (6.1 to 45.6) |
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, and vital signs, according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0
| Participants | Arm A: Tislelizumab + Sitravatinib | Arm B: Sitravatinib | Arm C: Investigator-chosen Chemotherapy (ICC) |
|---|---|---|---|
| TEAEs | 39 | 19 | 34 |
| SAEs | 22 | 6 | 15 |
Collected over All-cause mortality was assessed through the end of study, February 26th, 2024 (maximum time on study was 12 months). Adverse events were assessed from the first dose of study drug to 30 days after the last dose or the start of new anticancer therapy, whichever occurred first (maximum time on treatment was 8.9 months for Arm A, 7.7 months for Arm B, and 8.0 months for Arm C).. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Tislelizumab + Sitravatinib | 20/39 (51.3%) | 22/39 (56.4%) | 39/39 (100%) |
| Arm B: Sitravatinib | 5/19 (26.3%) | 6/19 (31.6%) | 19/19 (100%) |
| Arm C: Investigator-chosen Chemotherapy (ICC) | 19/38 (50%) | 15/34 (44.1%) | 34/34 (100%) |
| Event | Arm A: Tislelizumab + Sitravatinib | Arm B: Sitravatinib | Arm C: Investigator-chosen Chemotherapy (ICC) |
|---|---|---|---|
| DeathGeneral disorders | 5/39 | 0/19 | 2/34 |
| Neutrophil count decreasedInvestigations | 0/39 | 0/19 | 3/34 |
| White blood cell count decreasedInvestigations | 0/39 | 0/19 | 3/34 |
| PneumoniaInfections and infestations | 3/39 | 1/19 | 2/34 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/39 | 1/19 | 0/34 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/39 | 1/19 | 1/34 |
| Oesophageal obstructionGastrointestinal disorders | 0/39 | 1/19 | 1/34 |
| Chest painGeneral disorders | 0/39 | 1/19 | 0/34 |
| COVID-19 pneumoniaInfections and infestations | 2/39 | 1/19 | 1/34 |
| Skin infectionInfections and infestations | 0/39 | 1/19 | 0/34 |
| Event | Arm A: Tislelizumab + Sitravatinib | Arm B: Sitravatinib | Arm C: Investigator-chosen Chemotherapy (ICC) |
|---|---|---|---|
| White blood cell count decreasedInvestigations | 7/39 | 5/19 | 24/34 |
| Neutrophil count decreasedInvestigations | 3/39 | 5/19 | 21/34 |
| AnaemiaBlood and lymphatic system disorders | 12/39 | 5/19 | 20/34 |
| Aspartate aminotransferase increasedInvestigations | 15/39 | 9/19 | 2/34 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 9/39 | 8/19 | 0/34 |
| DiarrhoeaGastrointestinal disorders | 5/39 | 3/19 | 14/34 |
| Platelet count decreasedInvestigations | 9/39 | 7/19 | 6/34 |
| Weight decreasedInvestigations | 10/39 | 7/19 | 9/34 |
| NauseaGastrointestinal disorders | 3/39 | 4/19 | 12/34 |
| Alanine aminotransferase increasedInvestigations | 13/39 | 6/19 | 4/34 |
The Intent-to-Treat (ITT) analysis set included all randomized participants
| Age, Continuous(years) | Arm A: Tislelizumab + Sitravatinib | Arm B: Sitravatinib | Arm C: Investigator-chosen Chemotherapy (ICC) | Total |
|---|---|---|---|---|
| Mean | 59.1 ± 7.73 | 61.9 ± 7.87 | 60.4 ± 8.06 | 60.2 ± 7.87 |
| Sex: Female, Male(Participants) | Arm A: Tislelizumab + Sitravatinib | Arm B: Sitravatinib | Arm C: Investigator-chosen Chemotherapy (ICC) | Total |
|---|---|---|---|---|
| Female | 2 | 2 | 3 | 7 |
| Male | 37 | 17 | 35 | 89 |
| Race/Ethnicity, Customized(Participants) | Arm A: Tislelizumab + Sitravatinib | Arm B: Sitravatinib | Arm C: Investigator-chosen Chemotherapy (ICC) | Total |
|---|---|---|---|---|
| Asian | 39 | 19 | 38 | 96 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Oct 2022 to primary completion in Feb 2024, 16 months.
Results were first posted in Jun 2025, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sitravatinib · Tislelizumab · Docetaxel · Irinotecan
Esophageal Squamous Cell Carcinoma →